Enhanced Capacity to Manufacture Therapeutic Proteins
Biotech News
Phyton Biotech Acquires Novel Glyco-Engineering Technology, Adds Enhanced Capacity to Manufacture Therapeutic Proteins
Magnus Precht, President of Phyton Biotech, Inc., has announced the acquisition from The Dow Chemical Company of a novel, proprietary technology and intellectual property platform for the engineering of glycosylation in pharmaceutical protein products.
This acquisition will be enhanced through a research collaboration with the Dutch research institute Plant Research International (PRI), part of Wageningen University & Research Centre and one of the innovators of the technology platform.
The announcement coincides with another milestone, the installation of a second 75,000 liter bioreactor at Phyton's German cell fermentation facility.
"Our acquisition and collaboration should be viewed vis-a-vis recent developments in the glyco-engineering field, such as Merck's acquisition of GlycoFi and Roche's acquisition of Glycart," said Mr. Precht.
Dr. Laurence Korn, the co-founder and former CEO and Chairperson of PDL (a leader in humanized antibodies) and an industry leader, stressed that this technology complements the unique new protein expression platform that Phyton is developing.
"The glyco-engineering capability Phyton has acquired could allow the
company to realize the full potential of its plant cell fermentation
expression system," said Dr. Korn, adding that Phyton plans to apply the
technology to humanizing glycosylation in monoclonal antibodies, a
multi-billion dollar market.
The glyco-engineering technology has the potential to diminish the
clinical effects of immunogenicity, optimize drug potency and increase drug
half life. For patients, a longer half life can mean less frequent
injections.
Phyton is already a leader in plant cell fermentation technology,
producing paclitaxel for Bristol-Myers Squibb's TAXOL(R) oncology product.
Phyton Biotech, Inc., is based in East Windsor, N.J. Phyton's
proprietary plant cell culture technology platform is used to develop and
manufacture products with applications in the pharmaceutical and biotech
industries. Its German subsidiary, Phyton Biotech GmbH, operates the
world's largest commercial cGMP manufacturing facility for plant cell
fermentation. Visit http://www.phytonbiotech.com.
* Taxol is a registered trademark of Bristol-Myers Squibb Company.
SOURCE Phyton Biotech, Inc.
AZhttp, Inc.
Phyton Biotech Acquires Novel Glyco-Engineering Technology, Adds Enhanced Capacity to Manufacture Therapeutic Proteins
Magnus Precht, President of Phyton Biotech, Inc., has announced the acquisition from The Dow Chemical Company of a novel, proprietary technology and intellectual property platform for the engineering of glycosylation in pharmaceutical protein products.
This acquisition will be enhanced through a research collaboration with the Dutch research institute Plant Research International (PRI), part of Wageningen University & Research Centre and one of the innovators of the technology platform.
The announcement coincides with another milestone, the installation of a second 75,000 liter bioreactor at Phyton's German cell fermentation facility.
"Our acquisition and collaboration should be viewed vis-a-vis recent developments in the glyco-engineering field, such as Merck's acquisition of GlycoFi and Roche's acquisition of Glycart," said Mr. Precht.
Dr. Laurence Korn, the co-founder and former CEO and Chairperson of PDL (a leader in humanized antibodies) and an industry leader, stressed that this technology complements the unique new protein expression platform that Phyton is developing.
"The glyco-engineering capability Phyton has acquired could allow the
company to realize the full potential of its plant cell fermentation
expression system," said Dr. Korn, adding that Phyton plans to apply the
technology to humanizing glycosylation in monoclonal antibodies, a
multi-billion dollar market.
The glyco-engineering technology has the potential to diminish the
clinical effects of immunogenicity, optimize drug potency and increase drug
half life. For patients, a longer half life can mean less frequent
injections.
Phyton is already a leader in plant cell fermentation technology,
producing paclitaxel for Bristol-Myers Squibb's TAXOL(R) oncology product.
Phyton Biotech, Inc., is based in East Windsor, N.J. Phyton's
proprietary plant cell culture technology platform is used to develop and
manufacture products with applications in the pharmaceutical and biotech
industries. Its German subsidiary, Phyton Biotech GmbH, operates the
world's largest commercial cGMP manufacturing facility for plant cell
fermentation. Visit http://www.phytonbiotech.com.
* Taxol is a registered trademark of Bristol-Myers Squibb Company.
SOURCE Phyton Biotech, Inc.
AZhttp, Inc.
posted by Famous Quotations - Enhanced Capacity to Manufacture Therapeutic Proteins
0 Comments:
Post a Comment
Links to this post:
Create a Link
<< Home